Tao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tao Wu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Wenhui Liu
Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China
4 shared publicationsYang Liu
Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China
4 shared publicationsQiuyue Wu
Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China
3 shared publicationsHai Bai
Department of Hematology, the 940th Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, Gansu Province, China
2 shared publicationsHeng Liu
Department of Hematology, the 940th Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, Gansu Province, China
2 shared publicationsRui Xi
Department of Hematology, the 940th Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, Gansu Province, China
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 33 (1) , 1-12
Oncogenic mechanisms and therapeutic potential of SALL4 in hematological malignancies (Review)
As a member of the spalt like transcription factor (SALL) family, SALL4 regulates multiple oncogenic processes including cell proliferation, metastasis, epithelial‑mesenchymal transition, cancer stem cell maintenance and drug resistance. Physiologically, it is essential for the self‑renewal of embryonic and hematopoietic stem cells. Aberrant upregulation of SALL4 is frequently observed in both solid tumors and hematological malignancies; it has been proven to play a critical role in hematological malignancies, especially acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia and mixed‑lineage leukemia, where it promotes malignant cell proliferation, disease progression, and chemoresistance via downstream genes and key signaling pathways. Targeting key oncogenic molecules represents a promising therapeutic strategy for hematological malignancies. Elucidating the regulatory mechanisms of SALL4 may identify a novel therapeutic target. The present review summarizes the regulatory functions of SALL4 on key oncogenic targets and its upregulation profile in hematological malignancies. Although some mechanisms are mainly illustrated in solid tumors, they provide important insights for hematological cancer. Overall, SALL4 exhibits great potential as a novel therapeutic target and prognostic biomarker for hematological malignancies.
- 10 November 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 33 (1) , 1-12
Open AccessOncogenic mechanisms and therapeutic potential of SALL4 in hematological malignancies (Review)
As a member of the spalt like transcription factor (SALL) family, SALL4 regulates multiple oncogenic processes including cell proliferation, metastasis, epithelial‑mesenchymal transition, cancer stem cell maintenance and drug resistance. Physiologically, it is essential for the self‑renewal of embryonic and hematopoietic stem cells. Aberrant upregulation of SALL4 is frequently observed in both solid tumors and hematological malignancies; it has been proven to play a critical role in hematological malignancies, especially acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia and mixed‑lineage leukemia, where it promotes malignant cell proliferation, disease progression, and chemoresistance via downstream genes and key signaling pathways. Targeting key oncogenic molecules represents a promising therapeutic strategy for hematological malignancies. Elucidating the regulatory mechanisms of SALL4 may identify a novel therapeutic target. The present review summarizes the regulatory functions of SALL4 on key oncogenic targets and its upregulation profile in hematological malignancies. Although some mechanisms are mainly illustrated in solid tumors, they provide important insights for hematological cancer. Overall, SALL4 exhibits great potential as a novel therapeutic target and prognostic biomarker for hematological malignancies.
- Open Access
- 14 October 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1980188
Research progress on the BAG3-HSP70 axis-mediated autophagy in acute myeloid leukemia
Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy in which chemoresistance and relapse, often driven by leukemia stem cells (LSCs), remain major obstacles to cure. Autophagy is an evolutionarily conserved lysosomal degradation pathway whose function in AML is not fixed but is stage- and context-dependent: it restrains leukemogenesis in some settings while sustaining established and therapy-stressed LSCs in others. The Bcl-2-associated athanogene 3 (BAG3)-heat shock protein 70 (HSP70) axis integrates proteotoxic stress with the autophagy machinery, most notably through chaperone-assisted selective autophagy (CASA). This review applies a four-tier evidence framework—direct AML evidence, other hematological evidence, non-AML evidence, and proposed or hypothetical mechanisms—and explicitly separates BAG3-specific evidence from general HSP70 and autophagy findings. Direct AML evidence is comparatively strong for the cytoprotective, mitophagic and chemoresistance roles of autophagy and HSP70, but it is limited for a specific BAG3 dependency. In particular, direct BAG3 coupling to ULK1, competitive BAG3/HSP70 binding at the Beclin1 BH3 domain, and direct HSP70 shielding of ATG5 from cleavage are not supported by primary evidence. We examine the crosstalk between this axis and recurrent AML alterations (FLT3-ITD, NPM1 and TP53), and survey therapeutic strategies ranging from ATP-site HSP70 inhibitors to HSP70-BAG3 protein-protein interaction inhibitors, dual HSP70/HSP90 targeting, BAG3-directed agents, targeted protein degradation, nanoparticle delivery and emerging immunotherapies. We stratify direct axis-targeting from broad HSP70-family or proteostasis approaches. Finally, we summarize the principal knowledge gaps and the potential therapeutic window, cardiac-safety and biomarker challenges that must be addressed to convert the BAG3-HSP70 axis from a plausible mechanism into a precision target in AML.
- 14 October 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1980188
Open AccessResearch progress on the BAG3-HSP70 axis-mediated autophagy in acute myeloid leukemia
Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy in which chemoresistance and relapse, often driven by leukemia stem cells (LSCs), remain major obstacles to cure. Autophagy is an evolutionarily conserved lysosomal degradation pathway whose function in AML is not fixed but is stage- and context-dependent: it restrains leukemogenesis in some settings while sustaining established and therapy-stressed LSCs in others. The Bcl-2-associated athanogene 3 (BAG3)-heat shock protein 70 (HSP70) axis integrates proteotoxic stress with the autophagy machinery, most notably through chaperone-assisted selective autophagy (CASA). This review applies a four-tier evidence framework—direct AML evidence, other hematological evidence, non-AML evidence, and proposed or hypothetical mechanisms—and explicitly separates BAG3-specific evidence from general HSP70 and autophagy findings. Direct AML evidence is comparatively strong for the cytoprotective, mitophagic and chemoresistance roles of autophagy and HSP70, but it is limited for a specific BAG3 dependency. In particular, direct BAG3 coupling to ULK1, competitive BAG3/HSP70 binding at the Beclin1 BH3 domain, and direct HSP70 shielding of ATG5 from cleavage are not supported by primary evidence. We examine the crosstalk between this axis and recurrent AML alterations (FLT3-ITD, NPM1 and TP53), and survey therapeutic strategies ranging from ATP-site HSP70 inhibitors to HSP70-BAG3 protein-protein interaction inhibitors, dual HSP70/HSP90 targeting, BAG3-directed agents, targeted protein degradation, nanoparticle delivery and emerging immunotherapies. We stratify direct axis-targeting from broad HSP70-family or proteostasis approaches. Finally, we summarize the principal knowledge gaps and the potential therapeutic window, cardiac-safety and biomarker challenges that must be addressed to convert the BAG3-HSP70 axis from a plausible mechanism into a precision target in AML.
- Open Access
- 27 April 2026
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (2) , e00293
Allogeneic hematopoietic stem cell transplantation combined with dasatinib successfully treated adult acute lymphoblastic leukemia with e1a3 BCR-ABL1 fusion gene positivity: a case report and literature review
- 27 April 2026
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (2) , e00293
Open AccessAllogeneic hematopoietic stem cell transplantation combined with dasatinib successfully treated adult acute lymphoblastic leukemia with e1a3 BCR-ABL1 fusion gene positivity: a case report and literature review
- 10 April 2026
- Vol. 43 (4) , 307-311
[Advances in molecular genetic research on Myelodysplastic syndrome].
Myelodysplastic syndrome (MDS) is a chronic hematologic disorder characterized by ineffective hematopoiesis, dysplasia of one or more cell lines with or without definite genetic changes. Its diagnosis requires a comprehensive analysis combining morphology, immunology, cytogenetics, and molecular biology findings. In recent years, the development of second-generation sequencing (NGS) has provided great assistance in exploring the molecular pathogenesis of hematological malignancies and guidance for clinical practice. Mutations of a series of gene involved in RNA splicing, DNA methylation, transcriptional regulation, signal transduction, chromatin modification and cohesin complex have been identified as important mechanisms for the development of MDS, among which some mutations have been found to play important roles in the diagnosis, treatment, and prognosis of MDS. This article has provided a comprehensive review the the common molecular genetic abnormalities involved in MDS.
- 10 April 2026
- Vol. 43 (4) , 307-311
[Advances in molecular genetic research on Myelodysplastic syndrome].
Myelodysplastic syndrome (MDS) is a chronic hematologic disorder characterized by ineffective hematopoiesis, dysplasia of one or more cell lines with or without definite genetic changes. Its diagnosis requires a comprehensive analysis combining morphology, immunology, cytogenetics, and molecular biology findings. In recent years, the development of second-generation sequencing (NGS) has provided great assistance in exploring the molecular pathogenesis of hematological malignancies and guidance for clinical practice. Mutations of a series of gene involved in RNA splicing, DNA methylation, transcriptional regulation, signal transduction, chromatin modification and cohesin complex have been identified as important mechanisms for the development of MDS, among which some mutations have been found to play important roles in the diagnosis, treatment, and prognosis of MDS. This article has provided a comprehensive review the the common molecular genetic abnormalities involved in MDS.
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1712877
Hotspot gene mutations and treatment response in myelodysplastic syndromes (MDS): predictive biomarkers and targeted strategies
The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenia and a high risk of transformation to acute myeloid leukemia. In recent years, next-generation sequencing (NGS) has revealed common hotspot gene mutations in MDS, which are not only involved in disease progression, but also affect the responsiveness of different therapeutic strategies. Current research has revealed that ASXL1 mutations in MDS predict demethylating agents (HMAs) resistance, the combination of HMAs and Venetoclax (VEN) achieved an ORR of 87%. DNMT 3A R882 mutations induce decitabine sensitivity via hemi-methylated enhancer trapping, and TET2 mutations enhance HMAs efficacy only in ASXL1 wild-type contexts (ORR 62.1% vs. co-mutated 19%). RUNX1 aberrations reduce chemotherapy responses (18.9% ORR in high-risk MDS) through DNA repair impairment, while BCOR/EZH2 loss drives cytarabine resistance. TP53 multi-hit lesions correlate with poor survival (OS IDH1/2 inhibitors achieve durable remissions (ivosidenib ORR 83.3%, mOS 35.7 months). In this paper, we systematically illustrate the correlation between key gene mutations and the response to HMAs, chemotherapy and targeted therapies in MDS patients. This article summarizes the current evidence on gene mutations as predictive biomarkers and discusses the direction of individualized therapy.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1712877
Open AccessHotspot gene mutations and treatment response in myelodysplastic syndromes (MDS): predictive biomarkers and targeted strategies
The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenia and a high risk of transformation to acute myeloid leukemia. In recent years, next-generation sequencing (NGS) has revealed common hotspot gene mutations in MDS, which are not only involved in disease progression, but also affect the responsiveness of different therapeutic strategies. Current research has revealed that ASXL1 mutations in MDS predict demethylating agents (HMAs) resistance, the combination of HMAs and Venetoclax (VEN) achieved an ORR of 87%. DNMT 3A R882 mutations induce decitabine sensitivity via hemi-methylated enhancer trapping, and TET2 mutations enhance HMAs efficacy only in ASXL1 wild-type contexts (ORR 62.1% vs. co-mutated 19%). RUNX1 aberrations reduce chemotherapy responses (18.9% ORR in high-risk MDS) through DNA repair impairment, while BCOR/EZH2 loss drives cytarabine resistance. TP53 multi-hit lesions correlate with poor survival (OS IDH1/2 inhibitors achieve durable remissions (ivosidenib ORR 83.3%, mOS 35.7 months). In this paper, we systematically illustrate the correlation between key gene mutations and the response to HMAs, chemotherapy and targeted therapies in MDS patients. This article summarizes the current evidence on gene mutations as predictive biomarkers and discusses the direction of individualized therapy.
- 3 September 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 204, 104495
TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?
- 3 September 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 204, 104495
TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?
- 10 August 2024
- Vol. 41 (8) , 1010-1015
[Research progress on DNMT3A gene expression in Acute myeloid leukemia].
DNA methylation is an important epigenetic regulatory mechanism which plays a crucial role in cell differentiation and development. Its function is closely related to DNA methyltransferase 3 alpha (DNMT3A), which can affect gene expression and stem cell differentiation. The mutation rate of the DNMT3A gene is relatively high in Acute myeloid leukemia (AML), but its type and pathogenic mechanism are not yet clear. Further research on DNMT3A may help to identify its pathogenic targets and provide a basis for precise treatment of AML. This article has provided a review for the research progress on the expression of the DNMT3A gene in AML.
- 10 August 2024
- Vol. 41 (8) , 1010-1015
[Research progress on DNMT3A gene expression in Acute myeloid leukemia].
DNA methylation is an important epigenetic regulatory mechanism which plays a crucial role in cell differentiation and development. Its function is closely related to DNA methyltransferase 3 alpha (DNMT3A), which can affect gene expression and stem cell differentiation. The mutation rate of the DNMT3A gene is relatively high in Acute myeloid leukemia (AML), but its type and pathogenic mechanism are not yet clear. Further research on DNMT3A may help to identify its pathogenic targets and provide a basis for precise treatment of AML. This article has provided a review for the research progress on the expression of the DNMT3A gene in AML.
- 1 December 2023
- Vol. 31 (6) , 1845-1851
[Clinical Analysis of Autologous Peripheral Blood Hematopoietic Stem Cells Mobilization and Collection in Lymphoma Patients].
To analyze the factors influencing collection of autologous peripheral blood hematopoietic stem cells in lymphoma patients. Clinical data of 74 patients who received autologous peripheral blood hematopoietic stem cells mobilization and collection in the 940th Hospital of Joint Logistic Support Force of PLA from April 2009 to April 2021 were collected. The effects of gender, age, disease type, stage, course of disease, chemotherapy cycle number, relapse, radiotherapy, disease status and blood routine indexes on the day of collection on peripheral blood hematopoietic stem cell collection were analyzed. The success rate of collection was 95.9%(71/74), and the excellent rate of collection was 71.6%(53/74). There was a significantly statistical differentce in the number of CD34+ cells in grafts collected from patients with chemotherapy cycle ≤6 and >6 [(9.1±5.2)×106/kg vs (6.4±3.7)×106/kg, P=0.031]. The number of CD34+ cells in the first collection was positively correlated with WBC count, hemoglobin, platelet count, neutrophil count, lymphocyte count, monocyte count and hematocrit value on the day of collection ( r value was 0.424,0.486,0.306,0.289,0.353,0.428,0.528, respectively). WBC count, hemoglobin, monocyte count and hematocrit value have higher predictive value for the first collection of CD34+ cells. The area under the receiver operating characteristic was 0.7061,0.7845,0.7319,0.7848, respectively. Low dose CTX and VP16 chemotherapy combined with G-CSF can effectively mobilize autologous peripheral blood stem cells. The cycle number of chemotherapy relates to the collection of autologous peripheral blood stem cells. After mobilization, the success of the first collection can be better predicted by the blood routine indexes.
- 1 December 2023
- Vol. 31 (6) , 1845-1851
[Clinical Analysis of Autologous Peripheral Blood Hematopoietic Stem Cells Mobilization and Collection in Lymphoma Patients].
To analyze the factors influencing collection of autologous peripheral blood hematopoietic stem cells in lymphoma patients. Clinical data of 74 patients who received autologous peripheral blood hematopoietic stem cells mobilization and collection in the 940th Hospital of Joint Logistic Support Force of PLA from April 2009 to April 2021 were collected. The effects of gender, age, disease type, stage, course of disease, chemotherapy cycle number, relapse, radiotherapy, disease status and blood routine indexes on the day of collection on peripheral blood hematopoietic stem cell collection were analyzed. The success rate of collection was 95.9%(71/74), and the excellent rate of collection was 71.6%(53/74). There was a significantly statistical differentce in the number of CD34+ cells in grafts collected from patients with chemotherapy cycle ≤6 and >6 [(9.1±5.2)×106/kg vs (6.4±3.7)×106/kg, P=0.031]. The number of CD34+ cells in the first collection was positively correlated with WBC count, hemoglobin, platelet count, neutrophil count, lymphocyte count, monocyte count and hematocrit value on the day of collection ( r value was 0.424,0.486,0.306,0.289,0.353,0.428,0.528, respectively). WBC count, hemoglobin, monocyte count and hematocrit value have higher predictive value for the first collection of CD34+ cells. The area under the receiver operating characteristic was 0.7061,0.7845,0.7319,0.7848, respectively. Low dose CTX and VP16 chemotherapy combined with G-CSF can effectively mobilize autologous peripheral blood stem cells. The cycle number of chemotherapy relates to the collection of autologous peripheral blood stem cells. After mobilization, the success of the first collection can be better predicted by the blood routine indexes.
- 10 October 2023
- Vol. 40 (10) , 1222-1227
[Characteristics of genetic variants in 134 patients with Acute myeloid leukemia].
To analyze the characteristics of genetic variants in 134 patients diagnosed with Acute myeloid leukemia (AML). Clinical data of the 134 patients with AML (non-acute promyelocytic leukemia) initially diagnosed at the 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from June 2017 to June 2022 were retrospectively analyzed. Potential variants of AML-related genes were detected by next-generation sequencing, and the frequency of variants was analyzed by using SPSS v26.0 software, and likelihood ratio χ2 test and Fisher exact test were used for data analysis. The patients had included 72 males and 62 females, with a gender ratio of 1.7 : 1 and a median age of 51 years (9 ~ 86 years old). One hundred twenty patients (76.1%) had harbored at least one genetic variant, including 26 (19.4%) having a single variant, 27 (20.1%) having two variants, and 49 (36.6%) having >= 3 variants. 32 (23.9%) had no detectable variants. Genetic variants detected in over 10% of the 134 patients had included NPM1 (n = 24, 17.91%), FLT3-ITD (n = 21, 15.67%), DNMT3A (n = 20, 14.93%), CEBPA (single variant; n = 14, 10.45%), TET2 (n = 14, 10.45%), and NRAS (n = 14, 10.45%). The patients were also divided into low risk, intermediate risk and high risk groups based on their chromosomal karyotypes. The mutational rates for genes in different groups have varied, with 19 patients from the low risk group harboring variants of NRAS (n = 4, 21.05%), KRAS (n = 4, 21.05%), and KIT (n = 2, 10.53%); and 96 patients from the intermediate risk group harboring variants of NPM1 (n = 24, 25.00%), FLT3-ITD (n = 20, 20.83%), DNMT3A (n = 18, 18.75%), CEBPA (n = 12, 12.50%), and TET2 genes (n = 12, 12.50%). The mutational frequencies for the 19 patients from the high risk group were ASXL1 (n = 7, 21.05%), NRAS (n = 3, 15.97%), TP53 (n = 3, 15.79%), and EZH2 (n = 2, 10.53%). A significant difference was found in the frequencies of KIT, NPM1, FLT3-ITD, DNMT3A, and ASXL1 gene variants among the low-risk, medium-risk, and high-risk groups. AML patients have a high frequency for genetic variants, with 76.1% harboring at least one variant. The frequency of genetic variants have varied among patients with different chromosomal karyotypes, and there are apparent dominant variants. KIT, NPM1, FLT3-ITD, DNMT3A, and ASXL1 may be used as prognostic factors for evaluating their prognosis.
- 10 October 2023
- Vol. 40 (10) , 1222-1227
[Characteristics of genetic variants in 134 patients with Acute myeloid leukemia].
To analyze the characteristics of genetic variants in 134 patients diagnosed with Acute myeloid leukemia (AML). Clinical data of the 134 patients with AML (non-acute promyelocytic leukemia) initially diagnosed at the 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from June 2017 to June 2022 were retrospectively analyzed. Potential variants of AML-related genes were detected by next-generation sequencing, and the frequency of variants was analyzed by using SPSS v26.0 software, and likelihood ratio χ2 test and Fisher exact test were used for data analysis. The patients had included 72 males and 62 females, with a gender ratio of 1.7 : 1 and a median age of 51 years (9 ~ 86 years old). One hundred twenty patients (76.1%) had harbored at least one genetic variant, including 26 (19.4%) having a single variant, 27 (20.1%) having two variants, and 49 (36.6%) having >= 3 variants. 32 (23.9%) had no detectable variants. Genetic variants detected in over 10% of the 134 patients had included NPM1 (n = 24, 17.91%), FLT3-ITD (n = 21, 15.67%), DNMT3A (n = 20, 14.93%), CEBPA (single variant; n = 14, 10.45%), TET2 (n = 14, 10.45%), and NRAS (n = 14, 10.45%). The patients were also divided into low risk, intermediate risk and high risk groups based on their chromosomal karyotypes. The mutational rates for genes in different groups have varied, with 19 patients from the low risk group harboring variants of NRAS (n = 4, 21.05%), KRAS (n = 4, 21.05%), and KIT (n = 2, 10.53%); and 96 patients from the intermediate risk group harboring variants of NPM1 (n = 24, 25.00%), FLT3-ITD (n = 20, 20.83%), DNMT3A (n = 18, 18.75%), CEBPA (n = 12, 12.50%), and TET2 genes (n = 12, 12.50%). The mutational frequencies for the 19 patients from the high risk group were ASXL1 (n = 7, 21.05%), NRAS (n = 3, 15.97%), TP53 (n = 3, 15.79%), and EZH2 (n = 2, 10.53%). A significant difference was found in the frequencies of KIT, NPM1, FLT3-ITD, DNMT3A, and ASXL1 gene variants among the low-risk, medium-risk, and high-risk groups. AML patients have a high frequency for genetic variants, with 76.1% harboring at least one variant. The frequency of genetic variants have varied among patients with different chromosomal karyotypes, and there are apparent dominant variants. KIT, NPM1, FLT3-ITD, DNMT3A, and ASXL1 may be used as prognostic factors for evaluating their prognosis.
- 17 December 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23 (3) , e139-e149
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis
- 17 December 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23 (3) , e139-e149
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis